Survey of Alberta hospital pharmacists’ perspectives on additional prescribing authorization

2012 ◽  
Vol 69 (22) ◽  
pp. 1983-1992 ◽  
Author(s):  
Marissa Hutchison ◽  
Adrienne Lindblad ◽  
Lisa Guirguis ◽  
Dale Cooney ◽  
Marie Rodway
Keyword(s):  
Hospital Pharmacists ◽  
Alberta Hospital

scholarly journals Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia

2020 ◽  
Author(s):  
Amina M. Bagher ◽  
Thikryat Neamatallah ◽  
Ghadeer Balto ◽  
Lina Almikhy ◽  
Sara S. Almutairi ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Kingdom Of Saudi Arabia ◽  
Hospital Pharmacists

scholarly journals Tackling the challenges of nanomedicines: are we ready?

2021 ◽  
Author(s):  
John B Hertig ◽  
Vinod P Shah ◽  
Beat Flühmann ◽  
Stefan Mühlebach ◽  
Gunar Stemer ◽  
...  
Keyword(s):  
Complex Nature ◽  
Pharmaceutical Sciences ◽  
Patient Benefit ◽  
World Congress ◽  
Clinical Safety ◽  
Hospital Pharmacists ◽  
Drug Products ◽  
Regulatory Bodies ◽  
Regulatory Landscape

Abstract Purpose This review provides an overview of the proceedings of the symposium “Tackling the Challenges of Nanomedicines: Are We Ready?” organized by the International Pharmaceutical Federation (FIP) Hospital Pharmacy Section and Non-Biological Complex Drugs (NBCDs) Working Group at the 2019 FIP World Congress of Pharmacy and Pharmaceutical Sciences. Debate centered on reasons underlying the current complex regulatory landscape for nanomedicines and their follow-on products (referred to as nanosimilars) and the pivotal role of hospital pharmacists in selecting, handling, and guiding usage of nanomedicines and nanosimilars. Summary The evaluation and use of nanomedicines are recognized among scientific, pharmaceutical, and regulatory bodies as complex. Interchangeability and substitutability of nanomedicines and nanosimilars are confounded by a lack of pharmaceutical and pharmacological equivalence, reflecting the inherent complex nature of these drug products and manufacturing processes. Consequences include implications for clinical safety and efficacy and, ultimately, comparability. Local regulatory approvals of some nanomedicines have occurred, but there is no standard to ensure streamlined evaluation and use of consistent measures of therapeutic equivalence of reference products and their nanosimilars. Hospital pharmacists are expected to be experts in the selection, handling, and substitution of nanomedicines and familiarize themselves with the limitations of current methods of assessing pharmaceutical and clinical equivalence of nanosimilars in order to ensure informed formulary decision-making and eventual patient benefit. Conclusion Supportive guidance for pharmacists focusing on the substitutability and/or interchangeability of nanomedicines and their nanosimilars is needed. Current FIP guidance for pharmacists on therapeutic interchange and substitution should be extended to include nanomedicines and nanosimilars.

scholarly journals Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms

2021 ◽  
Vol 22 (4) ◽  
pp. 1980
Author(s):  
Mariarita Laforgia ◽  
Carmelo Laface ◽  
Concetta Calabrò ◽  
Simona Ferraiuolo ◽  
Valentina Ungaro ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Health Professionals ◽  
Life Experience ◽  
The Other ◽  
Vinca Alkaloids ◽  
Neurologic Complications ◽  
Typically Develop ◽  
Hospital Pharmacists ◽  
Single Mechanism

Peripheral neurologic complications are frequent adverse events during oncologic treatments and often lead to dose reduction, administration delays with time elongation of the therapeutic plan and, not least, worsening of patients’ quality of life. Experience skills are required to recognize symptoms and clinical evidences and the collaboration between different health professionals, in particular oncologists and hospital pharmacists, grants a correct management of this undesirable occurrence. Some classes of drugs (platinates, vinca alkaloids, taxanes) typically develop this kind of side effect, but the genesis of chemotherapy-induced peripheral neuropathy is not linked to a single mechanism. This paper aims from one side at summarizing and explaining all the scattering mechanisms of chemotherapy-induced peripheral neuropathy through a detailed literature revision, on the other side at finding new approaches to possible treatments, in order to facilitate the collaboration between oncologists, hematologists and hospital pharmacists.

scholarly journals Search for the Subconsciousness of Hospital Pharmacists on Their Practices of Blood Drawing or Injection, and etc.

2010 ◽  
Vol 130 (2) ◽  
pp. 253-261
Author(s):  
Masayoshi KOINUMA ◽  
Yoshiko MIYAZAKI ◽  
Tetsuro YUMOTO ◽  
Toru SATO ◽  
Shinichiro SUZUKI ◽  
...  
Keyword(s):  
Hospital Pharmacists ◽  
Blood Drawing

scholarly journals Medication safety knowledge, attitude, and practice among hospital pharmacists in tertiary care hospitals in Saudi Arabia: a multi-center study

2021 ◽  
Vol 79 (1) ◽  
Author(s):  
Azizah AL-Mutairi ◽  
Isamme AlFayyad ◽  
Youssef Altannir ◽  
Mohamad Al-Tannir
Keyword(s):  
Saudi Arabia ◽  
Medication Safety ◽  
Positive Attitude ◽  
Health Care Systems ◽  
Tertiary Care ◽  
World Health ◽  
Cross Sectional ◽  
Hospital Pharmacists ◽  
Adr Reporting ◽  
Tertiary Care Centers

Abstract Background Pharmacovigilance (PV) demarcates all actions involving the detection and prevention of adverse drug reactions (ADR) for marketed drugs. However, ADRs are considerably underreported worldwide and continue to be a major concern to health care systems. This study aims to assess the knowledge, attitude, and perception of hospital pharmacists regarding medication safety concerning PV and ADRs across multiple tertiary care centers around Saudi Arabia. Methods This cross-sectional study was conducted between July 2019 and January 2020. Pharmacists working in the tertiary care centers of Riyadh City, Saudi Arabia were asked to participate in the study. A self-administered questionnaire was used to conduct this study, it consisted of: 63 questions out of which 19 questions were knowledge-based, 15 were attitude-based, and 29 were practice-based questions. Results A total of 350 pharmacists were distributed and 289 agreed to participate, giving a response rate of 82.6%. Most pharmacists were aware of the concept of VP and its functions (96.5%) and (87.2%), respectively. Moreover, 90% said that ADR can be preventable and non-preventable. However, the findings revealed inadequate knowledge about the overall PV field, where the majority of the pharmacists failed to correctly answer questions related to independent ADRs treatment, Augmented drug reaction, the international location of ADR, and the World Health Organization “online database” for reporting ADRs. Moreover, incomplete and/or wrong answers were recorded for questions that included single or multiple correct answers. Regarding the participants” attitude, 96.9% were interested in ADR reporting, agreeing that ADR is important to enable safe drug usage. Although a general positive attitude was recorded, pharmacists have stated that the three main barriers that hinder reporting ADRs are: unavailability of information about ADRs, lack of awareness about the need to report ADRs, and lack of time. Concerning practice, 69.2% said they received training in ADRs reporting, and 70% have reported ADRs more than once a week. Conclusion Surveyed pharmacists from Riyadh hospitals showed narrow knowledge of the PV field. However, a positive attitude and satisfactory practice was observed among pharmacists. These findings warrant the need for educational programs and an encouraging environment for ADR reporting to increase ADR reporting rates and support PV activities in Saudi Arabia.

Sign in / Sign up

Export Citation Format

Share Document